ciprofloxacin has been researched along with Torsade de Pointes in 13 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 7.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "We report a rare case of torsade de pointes, a polymorphic ventricular tachycardia associated with QT interval prolongation, caused by intravenous ciprofloxacin given for pneumonia in a 22-year-old healthy Marine." | 7.73 | Ciprofloxacin-induced torsade de pointes. ( Flanagan, MC; Haigney, MC; Mitchell, ES, 2006) |
| "His rhythm revealed torsade de pointes, which required defibrillation." | 5.38 | Ciprofloxacin-induced torsade de pointes. ( Ibrahim, M; Omar, B, 2012) |
| "Ciprofloxacin may cause QTc prolongation and rarely torsades de pointes." | 5.32 | Ciprofloxacin-induced acquired long QT syndrome. ( Krahn, AD; Prabhakar, M, 2004) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 3.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "We report a rare case of torsade de pointes, a polymorphic ventricular tachycardia associated with QT interval prolongation, caused by intravenous ciprofloxacin given for pneumonia in a 22-year-old healthy Marine." | 3.73 | Ciprofloxacin-induced torsade de pointes. ( Flanagan, MC; Haigney, MC; Mitchell, ES, 2006) |
| "Ciprofloxacin is a fluoroquinolone antibiotic used against Gram - germs." | 1.51 | [Torsade de pointe resulting from a drug interaction between sotalol and ciprofloxacin]. ( Devaux, F; Fillet, M; Krzesinski, F, 2019) |
| "His rhythm revealed torsade de pointes, which required defibrillation." | 1.38 | Ciprofloxacin-induced torsade de pointes. ( Ibrahim, M; Omar, B, 2012) |
| "Ciprofloxacin may cause QTc prolongation and rarely torsades de pointes." | 1.32 | Ciprofloxacin-induced acquired long QT syndrome. ( Krahn, AD; Prabhakar, M, 2004) |
| "Ciprofloxacin was associated with a significantly lower rate of torsades de pointes (0." | 1.31 | Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. ( Frothingham, R, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Devaux, F | 1 |
| Fillet, M | 1 |
| Krzesinski, F | 1 |
| Keivanidou, A | 1 |
| Arnaoutoglou, C | 1 |
| Krommydas, A | 1 |
| Papanikolaou, G | 1 |
| Tsiptses, K | 1 |
| Chrisopoulos, C | 1 |
| Kirpizidis, C | 1 |
| Nair, MK | 1 |
| Patel, K | 1 |
| Starer, PJ | 1 |
| Salinas Arce, J | 1 |
| Romero, R | 1 |
| Solorzano, P | 1 |
| Ibrahim, M | 1 |
| Omar, B | 1 |
| Werner, CR | 1 |
| Riessen, R | 1 |
| Gregor, M | 1 |
| Bitzer, M | 1 |
| Haring, B | 1 |
| Bauer, W | 1 |
| Prabhakar, M | 1 |
| Krahn, AD | 1 |
| Flanagan, MC | 1 |
| Mitchell, ES | 1 |
| Haigney, MC | 1 |
| Tsikouris, JP | 1 |
| Peeters, MJ | 1 |
| Cox, CD | 1 |
| Meyerrose, GE | 1 |
| Seifert, CF | 1 |
| Milberg, P | 1 |
| Hilker, E | 1 |
| Ramtin, S | 1 |
| Cakir, Y | 1 |
| Stypmann, J | 1 |
| Engelen, MA | 1 |
| Mönnig, G | 1 |
| Osada, N | 1 |
| Breithardt, G | 1 |
| Haverkamp, W | 1 |
| Eckardt, L | 1 |
| Kaźmierczak, J | 1 |
| Peregud-Pogorzelska, M | 1 |
| Rzeuski, R | 1 |
| Frothingham, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB[NCT02409290] | Phase 3 | 588 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 17 |
| Regimen C (Oral Regimen) | 4 |
| Regimen D (6-month Regimen) | 0 |
The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen B (Control Regimen) | 14 |
| Regimen D (6-month Regimen) | 2 |
The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 17 |
| Regimen B (Control Regimen) | 126 |
| Regimen C (Oral Regimen) | 152 |
| Regimen D (6-month Regimen) | 115 |
The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 5 |
| Regimen C (Oral Regimen) | 5 |
| Regimen D (6-month Regimen) | 3 |
The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 133 |
| Regimen C (Oral Regimen) | 162 |
| Regimen D (6-month Regimen) | 122 |
1 review available for ciprofloxacin and Torsade de Pointes
| Article | Year |
|---|---|
Ciprofloxacin and the risk for cardiac arrhythmias: culprit delicti or watching bystander?
Topics: Administration, Oral; Adult; Anti-Infective Agents; Ciprofloxacin; Defibrillators, Implantable; Drug | 2012 |
1 trial available for ciprofloxacin and Torsade de Pointes
| Article | Year |
|---|---|
Effects of three fluoroquinolones on QT analysis after standard treatment courses.
Topics: Analysis of Variance; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Electrocardiography; Female; | 2006 |
11 other studies available for ciprofloxacin and Torsade de Pointes
| Article | Year |
|---|---|
[Torsade de pointe resulting from a drug interaction between sotalol and ciprofloxacin].
Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Ciprofloxacin; Drug Interactions; Electrocardiography | 2019 |
Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents; Atrial Fibrillation; Ciprofloxacin; | 2009 |
Ciprofloxacin-induced torsades de pointes in a methadone-dependent patient.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Interactions; Humans; Male; Methadone; Middle Aged; Narco | 2008 |
A case of prolonged QT interval and torsades de pointes due to ciprofloxacin.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Humans; Long QT Syndrome; Male; Torsades de Pointes | 2010 |
Ciprofloxacin-induced torsade de pointes.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Electrocardiography; Heart; Humans; Male; Torsades de Po | 2012 |
[Unexpected complication following esophageal variceal hemorrhage - Case 2/2011].
Topics: Amiodarone; Anti-Bacterial Agents; Ciprofloxacin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inh | 2011 |
Ciprofloxacin-induced acquired long QT syndrome.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Electric Countershock; Electrocardiography; Femal | 2004 |
Ciprofloxacin-induced torsade de pointes.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Defibrillators, Implantable; Electrocardiography; Follo | 2006 |
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Ani | 2007 |
QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator.
Topics: Aged; Anti-Arrhythmia Agents; Anti-Infective Agents; Ciprofloxacin; Defibrillators, Implantable; Dru | 2007 |
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Electrocardiography; Fluoroquinolones; Gatiflox | 2001 |